Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01E malaria vaccine

Table 7 Incidence rate per 100,000 person-year of other adverse events

Overall (N = 6897)	Incidence rate per 100,000 person-years
Overall (N = 6897)	n	Person-years	Value (95% CI)
Anemia	69	1490	4632	(3604, 5862)
Bacterial Infection	1	1492	67	(2, 373)
Burns	2	1492	134	(16, 484)
Conjunctivitis	1	1492	67	(2, 373)
Gastroenteritis	41	1491	2751	(1974, 3732)
Helminthic infection	2	1492	134	(16, 484)
Lower respiratory tract infection	38	1491	2549	(1804, 3499)
Malnutrition	3	1492	201	(41, 588)
Sepsis	22	1491	1475	(925, 2234)
Skin Infection	3	1492	201	(41, 588)
Upper respiratory tract infection	19	1492	1274	(767, 1989)
Urinary tract Infection	0	1492	0	(0, 247)

According-to-protocol cohort, 5 to 17 months age-group. Other adverse events, AE other than AESI, meningitis or malaria that was diagnosed during hospitalization.
Preferred terms of other AEs leading to hospitalization were grouped into medically relevant categories (refer to Additional file 5 for more details) for the calculation on the incidence rates. N, Number of study participants at risk within 30 days after each dose of the virtual primary vaccination schedule censored at the next dose; n, number of cases reported during that follow-up period
CI: confidence interval; M: Months; ATP: According-to-protocol cohort

ISSN: 1475-2875